Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 3
2022 2
2023 5
2024 8
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes.
Cinti F, Leccisotti L, Sorice GP, Capece U, D'Amario D, Lorusso M, Gugliandolo S, Morciano C, Guarneri A, Guzzardi MA, Mezza T, Capotosti A, Indovina L, Ferraro PM, Iozzo P, Crea F, Giordano A, Giaccari A. Cinti F, et al. Among authors: capece u. Cardiovasc Diabetol. 2023 Dec 19;22(1):349. doi: 10.1186/s12933-023-02091-0. Cardiovasc Diabetol. 2023. PMID: 38115004 Free PMC article. Clinical Trial.
SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives.
Morciano C, Gugliandolo S, Capece U, Di Giuseppe G, Mezza T, Ciccarelli G, Soldovieri L, Brunetti M, Avolio A, Splendore A, Pontecorvi A, Giaccari A, Cinti F. Morciano C, et al. Among authors: capece u. Cardiovasc Diabetol. 2024 Dec 19;23(1):449. doi: 10.1186/s12933-024-02539-x. Cardiovasc Diabetol. 2024. PMID: 39702365 Free PMC article. Review.
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
Leccisotti L, Cinti F, Sorice GP, D'Amario D, Lorusso M, Guzzardi MA, Mezza T, Gugliandolo S, Cocchi C, Capece U, Indovina L, Ferraro PM, Iozzo P, Crea F, Giordano A, Giaccari A. Leccisotti L, et al. Among authors: capece u. Cardiovasc Diabetol. 2022 Sep 3;21(1):173. doi: 10.1186/s12933-022-01607-4. Cardiovasc Diabetol. 2022. PMID: 36057768 Free PMC article. Clinical Trial.
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
Di Giuseppe G, Ciccarelli G, Soldovieri L, Capece U, Cefalo CMA, Moffa S, Nista EC, Brunetti M, Cinti F, Gasbarrini A, Pontecorvi A, Giaccari A, Mezza T. Di Giuseppe G, et al. Among authors: capece u. Trends Endocrinol Metab. 2023 Apr;34(4):216-230. doi: 10.1016/j.tem.2023.02.001. Epub 2023 Feb 27. Trends Endocrinol Metab. 2023. PMID: 36858875 Free article. Review.
Beta-cell function and glucose metabolism in patients with chronic pancreatitis.
Ciccarelli G, Di Giuseppe G, Soldovieri L, Quero G, Nista EC, Brunetti M, Cinti F, Moffa S, Capece U, Tondolo V, Mari A, Gasbarrini A, Pontecorvi A, Alfieri S, Giaccari A, Mezza T. Ciccarelli G, et al. Among authors: capece u. Eur J Intern Med. 2024 Oct;128:112-118. doi: 10.1016/j.ejim.2024.06.007. Epub 2024 Jun 12. Eur J Intern Med. 2024. PMID: 38871564 Free article.
Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study.
Cinti F, Morciano C, Guarneri A, Cappannoli L, Sorice G, Gugliandolo S, Capece U, Splendore A, Avolio A, Mezza T, Iozzo P, Pontecorvi A, Calcagni ML, Burzotta F, D'Amario D, Crea F, Leccisotti L, Giaccari A. Cinti F, et al. Among authors: capece u. Cardiovasc Diabetol. 2025 Aug 31;24(1):351. doi: 10.1186/s12933-025-02912-4. Cardiovasc Diabetol. 2025. PMID: 40887630 Free PMC article. Clinical Trial.
22 results